GoodRx Holdings (GDRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.08
- Estimate
- $0.08
- Surprise
- +0.4%
- Revenue (period 2026-06-30)
- $200.4M
- Score at report (before → after)
- 4.8 → 4.8/10
Revenue source: xbrl.
How the report landed
GoodRx Holdings (GDRX) reported adjusted EPS of $0.08, in line with the $0.08 estimate. TrendMatrix's engine moved from Buy (Wait) (4.8/10) to Hold at 4.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GDRX Sell at 4.6/10.
0 of the last 4 quarters beat the estimate; this quarter's +0.4% surprise compares with a -3.9% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: prescription transactions offering (68.0%)
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.49
- Stop
- $3.25
The stock trades at 74.4× trailing but 10.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
GDRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $1.27B
- P/E (fwd)
- 10.6
- P/E (ttm)
- 74.4
- 52-week range
- $1.77–$3.89
- Off 52-week high
- 10.3%
- RSI (14)
- 56
- Volume vs avg
- 1.12×
- Score today
- 4.6/10